SeekIn and OncoInv Collaborate to Expand the Global Accessibility of Multiple Cancer Detection Tests and Bridge Global Disparities in Cancer Care

SeekIn to Grant Oncolnv the Rights to Represent SeekIn's Comprehensive Range of Cancer Detection Tests in Twelve Countries to Provide Individuals with Accessible and Affordable Cancer Detection Tests

SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced a strategic collaboration with Oncolnv, a fully-owned affiliate of Inspire2Live, to expand the global accessibility of their multiple cancer detection tests and bridge disparities in cancer care.

Starting this December, SeekIn’s comprehensive range of cancer detection tests, namely OncoSeek, SeekInCare, SeekInCure and SeekInClarity will be distributed by Oncolnv in the following twelve countries: Belgium, Bulgaria, Costa Rica, Egypt, Ghana, Kenya, the Netherlands, Nigeria, Qatar, Singapore, Tanzania and UAE.

The agreement was formalized during the 2023 Inspire2Live Annual Congress held on November 29th and 30th in Amsterdam, the Netherlands. Representatives from 27 countries who are devoted to bringing the patient voice to the table joined this year’s congress on the theme of “If about us, not without us”. SeekIn’s founder and CEO, Dr. Mao Mao, delivered an inspiring speech, shedding light on the company’s cutting-edge cancer detection tests, while emphasizing the importance of early detection and improved patient outcomes. The OncoSeek test focuses on screening nine common cancer types with seven protein tumor markers (PTMs) whereas SeekInCare, SeekInCure and SeekInClarity are designed for cancer early detection, recurrence monitoring and treatment monitoring respectively incorporating shallow whole genomic sequencing and PTMs. Participants at the Inspire2Live congress were given the opportunity to take an OncoSeek test.

Commenting on the significance of this collaboration, Dr. Mao Mao stated, “We are thrilled to join forces with Inspire2Live and Oncolnv, two patient-centric organizations committed to revolutionizing cancer detection and treatment. With their extensive network and dedication to the cause, we can better serve cancer patients globally, providing them with advanced detection technologies and empowering healthcare providers with the tools that they need to fight this devastating disease.”

Inspire2Live’s founder, Mr. Peter Kapitein, expressed his excitement about the partnership, stating, “This collaboration aligns perfectly with our organization’s vision of a world where access to quality cancer care is universal. Together, we can make a real difference in the lives of countless patients around the globe.” Oncolnv is at the forefront of clinical settings and pays considerable attention to cancer screening, early diagnosis and personalized monitoring with patient care at the core. By partnering with SeekIn, Oncolnv gains valuable access to comprehensive cancer detection solutions for diverse health care systems, helping to bridge global disparities in cancer care.

In addition, this collaboration opens doors to future research initiatives, creating opportunities for joint clinical trials, information exchange, and collaborative development of innovative cancer detection methodologies. By leveraging the expertise of both organizations, this collaborative effort aims to improve patient outcomes and increase survival rates.

As SeekIn expands its global footprint, its commitment to research, innovation, and patient-centric care remains unwavering. The collaboration between SeekIn and Oncolnv brings together the collective expertise and resources needed to address the global cancer burden comprehensively.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”